Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system

Bibliography

• LIOTTA LA, STETLER-STEVENSON WG: Principles of mo-lecular cell biology of cancer: Cancer metastasis. In: Cancer: Principles and Practice of Oncology. Vincent J, De-Vita T, Hellman S and Rosenberg SA (Eds.), JB Lippincott, Philadelphia, PA (1993):134–149.
   Google Scholar
• WOODHOUSE EC, CHUAQUI RF, LIOTTA LA: General mechanisms of metastasis. Cancer (1997) 80(8 Suppl.):1529–1537.
   PubMedGoogle Scholar
• DIMITROFF CJ, SHARMA A, BERNACKI RJ: Cancer metas-tasis: a search for therapeutic inhibition. Cancer Invest. (1998) 16(4):279–290.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor Angiogenesis. In: The Molecular Ba-sis of Cancer. Mendelsohn J, Howley PM, Israel MA and Li-otta LA (Eds.), W.B. Saunders Company, Philadelphia, PA (1995)206–232.
   Google Scholar
• •A nice overall review of angiogenesis in tumours by the fa-ther of the field.
   Google Scholar
• PRESTA M, RIFKIN DB: New aspects of blood vessel growth: tumor and tissue-derived angiogenesis fac-tors. Haemostasis (1988) 18(0:6–17.
   PubMedGoogle Scholar
• KLAGSBRUN M, D'AMORE PA: Regulators of angiogene-sis. Annu. Rev. Physiol. (1991) 53:217–239.
   PubMed Web of Science ®Google Scholar
• AUERBACH W, AUERBACH R: Angiogenesis inhibition: a review. Pharmacol. Ther. (1994) 63 (3) 265–311.
   PubMedGoogle Scholar
• FIDLER IJ, ELLIS LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 79(2):185–1888.
   PubMedGoogle Scholar
• SIPOS EP, TAMARGO RJ, WEINGART JD, BREM H: Inhibi-tion of tumor angiogenesis. Ann. NY Acad. Sci. (1994) 732:263–272.
   PubMedGoogle Scholar
• BATTEGAY EJ: Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. j Mol. Med. (1995) 73(7):333–346.
   PubMedGoogle Scholar
• BIKFALVI A: Significance of angiogenesis in tumour progression and metastasis. Eur. J. Cancer (1995) 31A(7/8):1101–1104.
   PubMedGoogle Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86 (3) :353-364. A very nice, recent discussion of the angiogenic switch in cancer biology.
   Google Scholar
• WEINGART JD, LATERRA JJ, BREM H: Cerebral gliomas. Growth factors and angiogenesis. Baillieres Clin. Neurol (1996) 5(2):307–318.
   PubMedGoogle Scholar
• PLUDA JM: Tumor-associated angiogenesis: mecha-nisms, clinical implications, and therapeutic strate-gies. Semin. Oncol. (1997) 24(2):203–218.
   PubMedGoogle Scholar
• TAUNTON J: How to starve a tumor. Chem. Biol. (1997) 4 (7):493–496.
   PubMedGoogle Scholar
• ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev. Med. (1998) 49:407–424.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: An-giostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. (1996) 2(6):689–692.
   PubMed Web of Science ®Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390(6658)404–407.
   PubMedGoogle Scholar
• ••Provides evidence that anti-angiogenic therapies which tar-get the endothelial cells cause tumour regression without the initiation of drug resistance mechanisms.
   Google Scholar
• PEPPER MS, MONTESANO R: Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. (1990) 32:319–328.
   PubMedGoogle Scholar
• BASBAUM CB, WERB Z: Focalized proteolysis: spatial and temporal regulation of extracellular matrix degra-dation at the cell surface. Curr. Opin. Cell Biol. (1996) 8 (5):731–738.
   PubMedGoogle Scholar
• EDWARDS DR, MURPHY G: Cancer. Proteases-invasion and more. Nature (1998) 394(6693):527–528.
   PubMedGoogle Scholar
• BIRKEDAL-HANSEN H: Proteolytic remodeling of extra-cellular matrix. Curr. Opin. Cell. Biol. (1995) 7(5):728–735.
   PubMed Web of Science ®Google Scholar
• CHAMBERS AF, MATRISIAN LM: Changing views of the role of matrix met alloproteinases in metastasis. J. Natl. Cancer Inst. (1997) 89(17):1260–1270. A nice recent review of the roles of matrix met alloproteases in cancer biology.
   PubMed Web of Science ®Google Scholar
• DANO K, ANDREASEN PA, GRONDAHL-HANSEN J et al.: Plasminogen activators, tissue degradation, and can-cer. Adv Cancer Res. (1985) 44:139–266.
   PubMed Web of Science ®Google Scholar
• SAKSELA O: Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta. (1985) 823:35–65.
   PubMed Web of Science ®Google Scholar
• BLAST F, VASSALLI J-D, DANO K: Urokinase-type plasmi-nogen activator: Proenzyme, receptor and inhibitors. J. Cell Biol. (1987) 104:801–804.
   PubMedGoogle Scholar
• SAKSELA O, RIFKIN DB: Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. (1988) 4:93–126.
   PubMedGoogle Scholar
• BLAST F, VERDE P: Urokinase-dependent cell surface proteolysis and cancer. Semin. Cancer Biol. (1990) 1(2):117–126.
   PubMedGoogle Scholar
• TESTA JE, QUIGLEY JP: The role of urokinase-type plas-minogen activator in aggressive tumor cell behaviour. Cancer Metastasis Rev. (1990) 9:353–367.
   PubMed Web of Science ®Google Scholar
• VASSALLI J-D, SAPPINO A-P, BELIN D: The plasminogen activator/plasmin system. J. Clin. Invest. (1991) 88:1067–1072.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, JANICKE F, MONIWA et al.: Tumor-associated urokinase-type plasminogen activator: bio-logical and clinical significance. Biol. Chem. Hoppe-Seyler. (1992) 373:611–622.
   PubMed Web of Science ®Google Scholar
• DANO K, BEHRENDT N, BRUNNER N et al.: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis (1994) 8\(Suppl. 0:189–203.
   Google Scholar
• FAZIOLI F, BLAST F: Urokinase-type plasminogen acti-vator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci. (1994) 15(0:25–29.
   Google Scholar
• SCHMITT M, WILHELM O, JANICKE F et al. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metasta-sis. J. ObsteL Gynaecol (1995) 21 (2) 151–165
   Google Scholar
• ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer (1997) 72:1–22.
   PubMed Web of Science ®Google Scholar
• ••A very complete recent review of the entire urokinase-typeplasminogen activator field.
   Google Scholar
• RABBANI SA, XING RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol (1998) 12(4)911–920.
   PubMedGoogle Scholar
• STACK MS, ELLERBROEK SM, FISHMAN DA: The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma [Review]. Int. J. Oncol. (1998) 12:569–576.
   PubMedGoogle Scholar
• LUNEN HR, VAN HOEF B, COLLEN D: Activation with plasmin of two-chain urokinase-type plasminogen ac-tivator derived from single-chain urokinase-type plas-minogen activator by treatment with thrombin. Eur. J. Biochem. (1987) 169(2):359–364.
   PubMedGoogle Scholar
• FRENETTE G, TREMBLAY RR, LAZURE C, DUBE JY: Prostatic kallikrein hK2, but not prostate-specific anti-gen (hK3), activates single-chain urokinase-type plas-minogen activator. Int. J. Cancer (1997) 71(5)897–899.
   PubMedGoogle Scholar
• STACK MS, JOHNSON DA: Human mast cell tryptase ac-tivates single-chain urinary-type plasminogen activa-tor(pro-urokinase). J. Biol. Chem. (1 9 9 4)269(13)9416–9419.
   PubMedGoogle Scholar
• PLOW EF, HERREN T, REDLITZ A, MILES LA, HOOVER-PLOW JL: The cell biology of the plasminogen system. FASEB J (1995) 9(10:939–45.
   PubMed Web of Science ®Google Scholar
• MIGNATTI P, RIFKIN DB: Plasminogen activators and angiogenesis. Curr. Top. Microbiol. Immunol. (1996) 213:33–50.
   PubMed Web of Science ®Google Scholar
• STEFFENS GJ, GUNZLER WA, OTTING F, FRANKUS E, FLOHE L: The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z Physiol. Chem. (1982) 363 (9) :1043–1058.
   PubMedGoogle Scholar
• BLAST F: Surface receptors for urokinase plasminogen activator. Fibrinolysis (1988) 2:73–84.
   Google Scholar
• HEKMAN CM, LOSKUTOFF DJ: Fibrinolytic pathways and the endothelium. Semin. Thromb. HemosL (1987) 13 (4):514–527.
   PubMedGoogle Scholar
• HIGAZI AA-R, MAZAR A, WANG J et al.: Single-chain urokinase-type plasminogen activator bound to its re-ceptor is relatively resistant to plasminogen activator inhibitor Type 1. Blood (1996) 87(9):3545–3549.
   PubMedGoogle Scholar
• HE C, WILHELM SM, PENTLAND AP et al.: Tissue coopera-tion in a proteolytic cascade activating human intersti-tial collagenase. Proc. Natl. Acad. ScL USA. (1989) 86(8):2632–2636.
   PubMed Web of Science ®Google Scholar
• LYONS RM, KESKI-OJA J, MOSES HL: Proteolytic activa-tion of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. (1988) 106 (5):1659–1665.
   PubMed Web of Science ®Google Scholar
• ODEKON LE, BLAST F, RIFKIN DB: Requirement for receptor-bound urokinase in plasmin-dependent cel-lular conversion of latent TGF-beta to TGF-beta. J. Cell Physiol. (1994) 158(3):398–407.
   PubMedGoogle Scholar
• NUSRAT AR, CHAPMAN HA JR: An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. (1991) 87 (3) :1091–1097.
   PubMedGoogle Scholar
• GYETKO MR, TODD RF III, WILKINSON CC, SITRIN RG: The urokinase receptor is required for human mono-cyte chemotaxis in vitro. J. Clin. Invest. (1994) 93 (4) :1380–1387.
   PubMedGoogle Scholar
• BUSSO N, MASUR SK, LAZEGA D, WAXMAN S, OSSOWSKI L: Induction of cell migration by pro-urokinase bind-ing to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. (1994) 126 (1) :259–270.
   PubMedGoogle Scholar
• RESNATI M, GUTTINGER M, VALCAMONICA S et al: Prote-olytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. (1996) 15(7):1572–1582.
   PubMedGoogle Scholar
• •Presents evidence that uPA binding to uPAR activates intra-cellular kinases, and that cleavage of the uPAR between DI and D2/3 is required for activity. Given that the uPAR does not have an intracellular domain, these data suggest that an-other molecular entity is responsible for the transduction of this signal.
   Google Scholar
• HOYER-HANSEN G, PLOUG M, BEHRENDT N, RONNE E, DANO K: Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. j Biochem. (1997) 243 (1-2):21–26.
   PubMedGoogle Scholar
• CONESE M, NYKJAER A, PETERSEN CM et al.: alpha-2 Mac-roglobulin receptor/Ldl receptor-related pro-tein(Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. (1995) 131(6 Pt 0:1609–1622.
   PubMedGoogle Scholar
• CONESE M, BLAST F: Urokinase/urokinase receptor sys-tem: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe Seyler (1995) 376(3):143–155.
   PubMedGoogle Scholar
• •A nice review of the evidence that, upon binding of PAT-1 to uPA/uPAR, the complex is internalized and degraded, re-sulting in unbound uPAR being recycled to the cell-surface. This observation may underlie the mechanism of uPA's role in cellular migration.
   Google Scholar
• NYKJAER A, CONESE M, CHRISTENSEN El et al.: Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBOJ (1997) 16 (10) 2610–2620.
   PubMedGoogle Scholar
• CHAPMAN HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migra-tion. Curr. Opin. Cell Biol. (1997) 9:714–724.
   PubMed Web of Science ®Google Scholar
• ••A very nice review of the interactions of uPA, uPAR, PAT-1and the integrins, and their roles in cellular migration.
   Google Scholar
• BLAST F: uPA, uPAR, PAI-1: key intersection of prote-olytic, adhesive and chemotactic highways? Immunol Today (1997) 18(9):415–417.
   PubMedGoogle Scholar
• GYETKO MR, CHEN G-H, MCDONALD RA et al.: Uroki-nase is required for the pulmonary inflammatory re-sponse to Cryptococcus neoformans. A murine transgenic model. j Clin. Invest. (1996) 97 (8) :1818–1826.
   Google Scholar
• •Provides direct evidence of the role of uPA in the biological response to infection by pathogens.
   Google Scholar
• SHAPIRO RL, DUQUETTE JG, NUNES I et al.: Urokinase-type plasminogen activator-deficient mice are predis-posed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am. J. Pathol. (1997) 150 (1):359–369.
   PubMedGoogle Scholar
• CARMELIET P, SCHOONJANS L, KIECKENS L et al.: Physio-logical consequences of loss of plasminogen activator gene function in mice. Nature (1994) 368(6470) :419–424.
   PubMed Web of Science ®Google Scholar
• HILDENBRAND R, DILGER I, HORLIN A, STUTTE HJ: Urokinase and macrophages in tumour angiogenesis. Br. J. Cancer (1995) 72(4):818–823.
   PubMedGoogle Scholar
• HILDENBRAND R, DILGER I, HORLIN A, STUTTE HJ: Urokinase plasminogen activator induces angiogene-sis and tumor vessel invasion in breast cancer. Pathol. Res. Pract. (1995) 191(5)403–409.
   PubMedGoogle Scholar
• NAKATA S, ITO K, FUJIMORI M et al.: Involvement of vas-cular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel inva-sion in human colorectal cancers. Int. J. Cancer (1998) 79(2) :179–186.
   PubMedGoogle Scholar
• PEPPER MS, VASSALLI J-D, MONTESANO R, ORCI L: Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. (1987) 105(6):2535–2541.
   PubMedGoogle Scholar
• PEPPER MS, SAPPINO A-P, STOCKLIN R et al.: Upregula-tion of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. (1993) 122(3):673–684.
   PubMedGoogle Scholar
• KOOLWIJK P, VAN ERCK MGM, DE VREE WJA et al.: Coop-erative effect of TNFa, bFGF and VEGF on the forma-tion of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. (1996) 132(6):1177–1188.
   PubMedGoogle Scholar
• •Provides direct evidence that uPA plays a key role in a model of human angiogenesis.
   Google Scholar
• SCHNAPER HW, BARNATHAN ES, MAZAR A et al.: Plasmi-nogen activators augment endothelial cell organiza-tion in vitro by two distinct pathways. J. Cell Physic)]. (1995) 165:107–118.
   PubMed Web of Science ®Google Scholar
• •Provides evidence that uPA functions in two separate path-ways to control angiogenesis.
   Google Scholar
• GUALANDRIS A, CONEJO TL, GIUNCIUGLIO D et al: Urokinase-type plasminogen activator overexpres-sion enhances the invasive capacity of endothelial cells. Microvasc. Res. (1997) 53:254–260.
   PubMed Web of Science ®Google Scholar
• GROSS JL, MOSCATELLI D, RIFKIN DB: Increased capil-lary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc. Natl. Acad. Sci. USA. (1983) 80:2623–2627.
   PubMed Web of Science ®Google Scholar
• PEPPER MS, BELIN D, MONTESANO R, ORCI L, VASSALLIJ-D: Transforming growth factor-beta 1 modulates ba-sic fibroblast growth factor-induced proteolytic and angiogeneic properties of endothelial cells in vitro. J. Cell Biol. (1990) 111:743–755.
   PubMed Web of Science ®Google Scholar
• BLEI F, WILSON EL, MIGNATTI P, RIFKIN DB: Mechanismof action of angiostatic steroids: suppression of plas-minogen activator activity via stimulation of plasmi-nogen activator inhibitor synthesis. J. Cell Physic)]. (1993) 155(3):568–578.
   PubMedGoogle Scholar
• PEPPER MS, VASSALLI J-D, WILKS JW et al.: Modulation ofbovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell Bio-chem. (1994) 55(4):419–434.
   PubMedGoogle Scholar
• TAKANO S, GATELY S, NEVILLE ME et al. Suramin, an anticancer and angiosuppressive agent, inhibits endo-thelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. (1994) 54 (10) 2654–2660
   PubMedGoogle Scholar
• MANDRIOTA SJ, SEGHEZZI G, VASSALLI J-D et al.: Vascu-lar endothelial growth factor increases urokinase re-ceptor expression in vascular endothelial cells. J. Biol. Chem. (1995) 270(17)9709–9716.
   PubMedGoogle Scholar
• LEE H, STRUMAN I, CLAPP C, MARTIAL J, WEINER RI: Inhi-bition of urokinase activity by the antiangiogenic fac-tor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology (1 99 8) 139(9)3696–3703.
   PubMedGoogle Scholar
• SHAPIRO RL, DUQUETTE JG, ROSES DF et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. (1996) 56:3597–3604.
   PubMed Web of Science ®Google Scholar
• •Provides direct evidence that uPA plays a role in the pro-gression of tumours.
   Google Scholar
• SABAPATHY KT, PEPPER MS, KIEFER F et al.: Polyoma middle T-induced vascular tumor formation: The role of the plasminogen activator/plasmin system. J. Cell Biol. (1997) 137(4):953–963.
   PubMedGoogle Scholar
• ••Provides additional direct evidence that uPA plays a key rolein the progression of cancer.
   Google Scholar
• OSSOWSKI L, REICH E: Antibodies to plasminogen acti-vator inhibit human tumor metastasis. Cell (1983) 35:611–619.
   PubMed Web of Science ®Google Scholar
• YU H, SCHULTZ RM: Relationship between secretedurokinase plasminogen activator activity and meta-static potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. (1990) 50(23):7623–7633.
   PubMedGoogle Scholar
• OSSOWSKI L, RUSSO-PAYNE H, WILSON EL: Inhibition ofurokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res. (1991) 51:274–281.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, OHI H, SUGIMURA M et al.: Inhibition ofin vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. (1992) 52:3610–3614.
   PubMed Web of Science ®Google Scholar
• NISHIMURA Y, YASUI W, YOSHIDA K et al.: A serineprotease-inhibitory benzamidine derivative inhibits the growth of human colon carcinoma cells. Jpn. J. Cancer Res. (1992) 83:723–728.
   PubMedGoogle Scholar
• BILLSTROM A, HARTLEY-ASP B, LECANDER I, BATRA S, ASTEDT B: The urokinase inhibitor p-aminobenzamidine inhibits growth of a human pros-tate tumor in scid mice. Int. J. Cancer (1995) 61:542–547.
   PubMed Web of Science ®Google Scholar
• WILHELM O, SCHMITT M, HOHL S, SENEKOWITSCH R, GRAEFF H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Me-tastasis (1995) 13(4):296–302.
   PubMedGoogle Scholar
• RABBANI SA, HARAKIDAS P, DAVIDSON DJ, HENKIN J, MAZAR AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer (1995) 63:840–845.
   PubMed Web of Science ®Google Scholar
• JANKUN J, KECK RW, SKRZYPCZAK-JANKUN E, SWIERCZR: Inhibitors of urokinase reduce size of prostate can-cer xenografts in severe combined immunodeficient mice. Cancer Res. (1997) 57(4):559–563.
   PubMedGoogle Scholar
• KAWAZOE Y, SAWADA T, CHUNG Y-S, SOWA M: Role ofurokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer. Intl Oncology. (1997) 10:983–987.
   PubMedGoogle Scholar
• CROWLEY CW, COHEN RL, LUCAS et al.: Prevention ofmetastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA (1993) 90:5021–5025.
   PubMed Web of Science ®Google Scholar
• •Provides evidence, using enzymatically inactive uPA, that the enzymatic activity is key in the progression of cancer.
   Google Scholar
• KOBAYASHI H, GOTOH J, FUJIE M et al: Inhibition ofmetastasis of Lewis lung carcinoma by a synthetic pep-tide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer (1994) 57:727–733.
   PubMed Web of Science ®Google Scholar
• MIN HY, DOYLE LV, VITT CR et al.: Urokinase receptorantagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. (1996) 56:2428–2433.
   PubMed Web of Science ®Google Scholar
• EVANS CP, ELFMAN F, PARANGI S et al.: Inhibition ofprostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. (1997) 57:3594–3599.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, SHINOHARA H, FUJIE M et al.: Inhibitionof metastasis of Lewis lung carcinoma by urinary tryp-sin inhibitor in experimental and spontaneous metas-tasis models. Ont. J. Cancer (1995) 63:455–462.
   PubMed Web of Science ®Google Scholar
• IGNAR DM, ANDREWS JL, WITHERSPOON SM et al.: Inhi-bition of establishment of primary and micrometa-static tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp. Metastasis (1998) 16(1)9–20.
   PubMedGoogle Scholar
• JANICKE F, SCHMITT M, GRAEFF H Clinical relevance ofthe urokinase-type and tissue-type plasminogen acti-vators and of their Type 1 inhibitor in breast cancer. Semin. Thromb. HemosL (1991) 17(3):303–312.
   PubMed Web of Science ®Google Scholar
• GRONDAHL-HANSEN J, CHRISTENSEN IJ, ROSENQUIST C et al: High levels of urokinase-type plasminogen acti-vator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. (1993) 53(10:2513–2521.
   PubMedGoogle Scholar
• JANICKE F, SCHMITT M, PACHE L et al.: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. (1993) 24 (3) :195–208.
   PubMedGoogle Scholar
• HEISS MM, BABIC R, ALLGAYER H et al.: Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. (1995) 13(8):2084–2093.
   PubMedGoogle Scholar
• GRONDAHL-HANSEN J, HILSENBECK SG, CHRISTENSEN IJ et al.: Prognostic significance of PAI-1 and uPA in cy-tosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res. Treat. (1997) 43(2):153–163.
   PubMedGoogle Scholar
• •A recent review of the clinical evidence that the uPA system is correlated with poor prognosis in breast cancer.
   Google Scholar
• BAJOU K, NOEL A, GERARD RD et al.: Absence of host plasminogen activator inhibitor 1 prevents cancer in-vasion and vascularization. Nature Med. (1998) 4 (8):923–928.
   PubMedGoogle Scholar
• ••Provides evidence that PAI-1 directly plays a role in the pro-gression of cancer. This observation is counterintuitive to its role as a plasminogen activator inhibitor and is very important.
   Google Scholar
• RAO NK, SHI GP, CHAPMAN HA: Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. In-vest. (1995) 96(0:465–474.
   PubMedGoogle Scholar
• DENG G, CURRIDEN SA, WANG S, ROSENBERG S, LO-SKUTOFF DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. (1996) 134(6):1563–1571.
   PubMedGoogle Scholar
• ••Provides direct evidence that PAT-1 governs the balance be-tween cellular adhesion and detachment and may play a key role in cellular migration.
   Google Scholar
• PLANUS E, BARLOVATZ-MEIMON G, ROGERS RA et al. Binding of urokinase to plasminogen activator inhibi-tor type-1 mediates cell adhesion and spreading. J. Cell Sci. (1997) 110 (Pt 9) 1091–1098
   PubMedGoogle Scholar
• WALTZ DA, NATKIN LR, FUJITA RM, WET Y, CHAPMAN HA: Plasmin and plasminogen activator inhibitor Type 1 promote cellular motility by regulating the interac-tion between the urokinase receptor and vitronectin.Clin. Invest. (1997) 100(0:58–67.
   Google Scholar
• BOHUSLAV J, HOREJSI V, HANSMANN C et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of hu-man monocytes. J. Exp. Med. (1995) 181 (4) 1381–1390
   PubMedGoogle Scholar
• WET Y, LUKASHEV M, SIMON DI et al.: Regulation of in-tegrin function by the urokinase receptor. Science (1996) 273(5280:1551–1555.
   PubMedGoogle Scholar
• •Provides evidence that uPAR interacts directly with integrins and regulates their function.
   Google Scholar
• KONAKOVA M, HUCHO F, SCHLEUNING WD: Down-stream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur. J. Biochem. (1998) 253(2):421–429.
   PubMedGoogle Scholar
• STEFANSSON S, LAWRENCE DA: The serpin PAI-1 inhib-its cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 383(6599)441–443.
   PubMedGoogle Scholar
• YEBRA M, PARRY GCN, STROMBLAD S et al.: Require-ment of receptor-bound urokinase-type plasminogen activator for integrin avp-directed cell migration. J. Biol. Chem. (1996) 271(46):29393–29399.
   PubMed Web of Science ®Google Scholar
• KJOLLER L, KANSE SM, KIRKEGAARD T et al. Plasmino-gen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. (1997) 232(2):420–429.
   PubMedGoogle Scholar
• CUBELLIS MV, WUN T-C, BLAST F: Receptor-mediated in-ternalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 9 (4):1079–1085.
   PubMedGoogle Scholar
• •Provides evidence that PAT-1 is required to initiate the inter-nalisation of uPA/uPAR resulting in the re-expression of un-bound uPAR on the cell surface, and perhaps being responsible for cellular migration.
   Google Scholar
• NOWAK UK, LI X, TEUTEN AJ, SMITH RA, DOBSON CM: NMR studies of the dynamics of the multidomain pro-tein urokinase-type plasminogen activator. Biochemis-try (1993) 32(1):298–309.
   PubMedGoogle Scholar
• STEPHENS RW, BOKMAN AM, MYOHANEN HT et al.: Heparin binding to the urokinase kringle domain. Bio-chemistry (1992) 31 (33):7572–7579.
   Google Scholar
• LI X, BOKMAN AM, LLINAS M, SMITH RA, DOBSON CM: Solution structure of the kringle domain from urokinase-type plasminogen activator. J. Mol. Biol. (1994) 235(5):1548–1559.
   PubMedGoogle Scholar
• HANSEN AP, PETROS AM, MEADOWS RP et al.: Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 33(16):4847–4864.
   PubMed Web of Science ®Google Scholar
• SPRAGGON G, PHILLIPS C, NOWAK UK et al.: The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure (1995) 3(7):681–691.
   PubMed Web of Science ®Google Scholar
• •The first published crystal structure of the protease domain of uPA shows interactions made by a bound peptide chloro-methyl ketone transition state analog inhibitor.
   Google Scholar
• KRAUT J: Serine proteases: structure and mechanism of catalysis. Ann. Rev. Biochem. (1977) 46:331–358.
   PubMed Web of Science ®Google Scholar
• LESK AM, FORDHAM WD: Conservation and variability in the structures of serine proteinases of the chy-motrypsin family. j Mol. Biol. (1996) 258(3):501–537.
   PubMedGoogle Scholar
• SCHECHTER I, BERGER A: On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. (1967) 27(2):157–162.
   PubMed Web of Science ®Google Scholar
• FREER ST, KRAUT J, ROBERTUS JD, WRIGHT HT, XUONG NH: Chymotrypsinogen: 2.5-angstrom crystal struc-ture, comparison with alpha-chymotrypsin, and im-plications for zymogen activation. Biochemistry (1970) 9(9):1997–2009.
   PubMedGoogle Scholar
• LAMBA D, BAUER M, HUBER R et al.: The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J. Mol. Biol. (1996) 258(0:117–135.
   PubMedGoogle Scholar
• ADAMS DS, GRIFFIN LA, NACHAJKO WR, REDDY VB, WET CM: A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasmino-gen activator inhibitor. J. Biol. Chem. (1 99 1) 266(13)8476–8482.
   PubMedGoogle Scholar
• RIJKEN DC, GROENEVELD E: Substrate specificity of tissue-type and urokinase-type plasminogen activa-tors. Biochem. Biophys. Res. Commun. (1991) 174(2):432–438.
   PubMedGoogle Scholar
• LORAND L, CONDIT EV: Ester hydrolysis by urokinase. Biochemistry (1965) 4:265–270.
   Web of Science ®Google Scholar
• YANG H, HENKIN J: Competitive inhibitors of human urokinase. Fibrinolysis (1992) 6\(Suppl. 0:31–34.
   Google Scholar
• ••Early review of uPA inhibitors that are competitive.
   Google Scholar
• OKAMATO S, HIJIKATA A: Rational approaches to proteinase inhibitors. In: Drug Design. Ariens EJ (Ed.), Academic Press, (1975):143–159.
   Google Scholar
• GERATZ JD, CHENG MCF: The inhibition of urokinase by aromatic diamidines. Thromb. Diath. Haemorrh. (1975) 33(2):230–243.
   PubMedGoogle Scholar
• GERATZ JD, SHAVER SR, TIDWELL RR: Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb. Res. (1981) 24(1–2)73–83.
   Google Scholar
• •This early paper details a broad array of uPA inhibitors based on different PI binding elements, from indoles to benzamidine, and references other early work. Also pre-sented are data comparing high molecular weight and low molecular weight urokinase inhibitory values.
   Google Scholar
• STURZEBECHER J, MARKWARDT F: Synthetische inhibi-toren der serinproteinasen. Pharmazie (1978) 33(H.9):599–602.
   Google Scholar
• TID WELL RR, GERATZ JD, DANN O et al: Diarylamidine derivatives with one or both of the aryl moieties con-sisting of an indole or indole-like ring. Inhibitors of ar-ginine-specific esteroproteases. J. Med. Chem. (1978) 21(7):613–623.
   PubMedGoogle Scholar
• VASSALLI J-D, BELIN D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. (1987) 214(1):187–191.
   PubMed Web of Science ®Google Scholar
• YANG H, HENKIN J, KIM KH, GREER J: Selective inhibi-tion of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J. Med. Chem. (1990) 33(10:2956–2961.
   PubMedGoogle Scholar
• TOWLE MJ, LEE A, MADUAKOR EC et al.: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor. Cancer Res. (1993) 53:2553–2559.
   PubMed Web of Science ®Google Scholar
• ••Most potent and selective competitive uPA inhibitors pub-lished, which also show activity for cell surface bound uPA in addition to free uPA.
   Google Scholar
• OGSTEN D: Inhibition of the plasminogen activator urokinase by alpha-tocopherol. Acta. haemal (1982) 67:114–118.
   Google Scholar
• MARES-GUIA M, SHAW E: The specific inactivation of trypsin by ethyl p-guanidinobenzoate. J. Biol. Chem. (1967) 242(24):5782–5788.
   PubMedGoogle Scholar
• ADLER G, REINSHAGEN M, GOKE B: Effect of camostat on exocrine pancreatic function in humans. Biomed. Res. (1989) 10(Suppl.
   Google Scholar
• SENOKUCHI K, NAKAI H, NAKAYAMA Y et al.: New orally active serine protease inhibitors. J. Med. Chem. (1995) 38(14)2521–2523.
   PubMedGoogle Scholar
• KETTNER C, SHAW E: The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketone. Biochim. Biophys. Acta. (1979) 569(0:31–40.
   PubMedGoogle Scholar
• COLEMAN P, KETTNER C, SHAW E: Inactivation of the plasminogen activator from HeLa cells by peptides of arginine chloromethyl ketone. Biochim. Biophys. Acta. (1979) 569(0:41–51.
   PubMedGoogle Scholar
• LUNEN HR, UYTTERHOEVEN M, COLLEN D: Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. Thromb. Res. (1984) 34 (5) :431–437.
   PubMedGoogle Scholar
• REBOUD-RAVAUX M, DESVAGES G, CHAPEVILLE F: Irre-versible inhibition and peptide mapping of urinary plasminogen activator urokinase. FEBS Lett. (1982) 140(1)58–62.
   PubMedGoogle Scholar
• REBOUD-RAVAUX M, VILAIN AC, BOGGETTO N et al.: A cyclopeptidic suicide substrate preferentially inacti-vates urokinase-type plasminogen activator. Biochem. Biophys. Res. Commun. (1991) 178(0:352–359.
   PubMedGoogle Scholar
• WAKSELMAN M, XIE J, MAZALEYRAT JP et al.: New mechanism-based inactivators of trypsin-like prote-inases. Selective inactivation of urokinase by function-alized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid resi-due. J. Med. Chem. (1993) 36(10:1539–1547.
   PubMedGoogle Scholar
• MEHDI S: Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg. Chem. (1993) 21:249–259.
   Web of Science ®Google Scholar
• SHEA JP: 'Approaches to coagulation cascade protease inhibition using rational drug design and SMARTTm li-brary chemistry' .Beyond Heparin-Novel anticoagulants and emerging applications. San Diego, CA. (May 27–29, 1998).
   Google Scholar
• DEADMAN JJ, ELGENDY S, GOODWIN CA et al. Charac-terization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of throm-bin. J. Med. Chem. (1995) 38(9):1511–1522.
   PubMedGoogle Scholar
• KE SH, COOMBS GS, TACHIAS K, COREY DR, MADISON EL: Optimal subsite occupancy and design of a selec-tive inhibitor of urokinase. J. Biol. Chem. (1997) 272(33)20456–20462.
   PubMedGoogle Scholar
• NIEUWENHUIZEN W, WIJNGAARDS G, GROENEVELD E: Synthetic substrates and the discrimination between urokinase and tissue plasminogen activator activity. Thromb. Res. (1977) 11(1):87–89.
   Google Scholar
• VASSALLI J-D, BACCINO D, BELIN D: A cellular binding site for the Mr 55, 000 form of the human plasminogen activator, urokinase. J. Cell Biol. (1985) 100(1):86–92.
   PubMedGoogle Scholar
• STOPPELLI MP, CORTI A, SOFFIENTINI A et al.: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA (1985) 82(15):4939–4943.
   PubMedGoogle Scholar
• APPELLA E, ROBINSON EA, ULLRICH SJ et al.: The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. (1987) 262(10):4437–4440.
   PubMedGoogle Scholar
• BEHRENDT N, RONNE E, DANO K: Binding of the urokinase-type plasminogen activator to its cell sur-face receptor is inhibited by low doses of suramin. J. Biol. Chem. (1993) 268(8):5985–5989.
   PubMedGoogle Scholar
• PLOUG M, ELLIS V, DANO K: Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evi-dence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry (1994) 33(30):8991–8997.
   PubMedGoogle Scholar
• SMITH EM: From libraries of mixtures to potent single compounds. Development of uPAR antagonists. SRI Conference, Philadelphia, PA. (1998).
   Google Scholar
• KATZ BA, FINER-MOORE J, MORTEZAEI R, RICH DH, STROUD RM: Episelection: novel Ki approximately nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. Biochemis-try (1995) 34 (26):8264–8280.
   PubMed Web of Science ®Google Scholar
• VIJAYALAKSHMI J, PADMANABHAN KP, MANN KG, TU-LINSKY A: The isomorphous structures of prethrom-bin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein ScL (1994) 3 (12) :2254–2271.
   PubMedGoogle Scholar
• PADMANABHAN K, PADMANABHAN KP, TULINSKY A et al.: Structure of human des(1-45) factor Xa at 2.2 A resolution. J. Mol. Biol. (1993) 232(3):947–966.
   PubMed Web of Science ®Google Scholar
• KATZ BA, LIU B, BARNES M, SPRINGMAN EB: Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein ScL (1998) 7(4):875–885.
   PubMedGoogle Scholar
• NA VIA MA, MCKEEVER BM, SPRINGER JP et al.: Structure of human neutrophil elastase in complex with a pep-tide chloromethyl ketone inhibitor at 1.84-A resolu-tion. Proc. Natl. Acad. ScL USA (1989) 86(1):7–11.
   PubMedGoogle Scholar